Novel Approaches to Drug Discovery for Parkinson's Disease 2009
Program Announced: 11/03/2008
Funding Anticipated: May 2009
Novel Approaches to Drug Discovery for Parkinson's Disease 2009 -- RFA: To view the file, click here.
Novel Approaches to Drug Discovery for Parkinson's Disease 2009 -- FAQs: To view the file, click here.
The Michael J. Fox Foundation for Parkinson’s Disease announces the launch of the Novel Approaches to Drug Discovery for Parkinson’s Disease (NADD) program. The goal of the program is to support efforts to convert and further develop promising biological targets into novel disease-modifying therapeutic strategies. In addition, MJFF seeks to promote partnerships that can accelerate development of new therapies by providing investigators with the opportunity to partner with Elan Pharmaceuticals Inc. Elan Pharmaceuticals is a neuroscience-based biotechnology company committed to developing novel approaches for neurodegenerative diseases and is partnering with MJFF in this drug discovery and development program. In return, Elan will have an option for a right of first negotiation for any promising approaches or materials that arise out of this program.
NADD will support promising and innovative research projects conducted on a one-year timeframe; projects that successfully meet all proposed aims with promising results that suggest clear translational next steps may be considered for an additional year of funding. Further program details and guidance about the types of proposals and focus areas that are of greatest interest to MJFF can be found in the following Request for Applications (RFA).
Applicants may request a project period of up to one year and direct costs appropriate and justifiable for the work proposed, in addition to indirect costs of up to 25 percent of direct costs.
